Table 9.
Effect on maximum weight loss, off-label patients—adjusted analyses.
| Young adults (19–25 years old) | Adolescents (13–18 years old) | Children (5–12 years old) | ||||
|---|---|---|---|---|---|---|
| ‡N = 376 medication instances | ‡N = 168 medication instances | ‡N = 27 medication instances | ||||
| %TBW (95% CI) | P-value | ΔBMIz (95% CI) | P-value | ΔBMIz (95% CI) | P-value | |
| Medication* | ||||||
| Metformin | −0.90 (−1.7–0.1) | 0.04 | −0.04 (−0.1–0.0) | 0.006 | 0.00 (−0.1–0.1) | >0.1 |
| Topiramate | 0.57 (−0.3–1.4) | >0.1 | 0.02 (0.0–0.1) | >0.1 | 0.00 (−0.1–0.1) | >0.1 |
| Bupropion | −9.15 (−14.6–3.6) | 0.001 | — | — | — | — |
| Phentermine | 1.56 (0.2–2.9) | 0.02 | 0.15 (0.0–0.3) | 0.03 | — | — |
| Zonisamide | 0.07 (−6.9–7.1) | >0.1 | — | — | — | — |
| Naltrexone | 1.80 (−3.9–7.5) | >0.1 | — | — | — | — |
| Orlistat | −2.06 (−3.7–0.4) | 0.01 | — | — | — | — |
| Obesity class | ||||||
| Overweight | ref | — | ref | — | ref | — |
| Class I (mild) | 2.41 (−0.2–5.0) | 0.07 | 0.18 (0.0–0.3) | 0.02 | — | — |
| Class II (moderate) | 4.33 (1.9–6.7) | <0.001 | 0.18 (0.0–0.3) | 0.03 | 0.04 (−0.2–0.3) | >0.1 |
| Class III (severe) | 3.04 (0.7–5.4) | 0.01 | 0.14 (0.0–0.3) | 0.07 | 0.11 (−0.1–0.3) | >0.1 |
| Age at med initiation, years | 0.33 (0.0–0.7) | 0.07 | 0.00 (0.0–0.0) | >0.1 | −0.01 (−0.1–0.1) | >0.1 |
| Female sex | −0.75 (−2.9–1.4) | >0.1 | −0.04 (−0.1–0.0) | >0.1 | −0.14 (−0.3–0.0) | >0.1 |
| Race | ||||||
| White | ref | — | ref | — | ref | — |
| Black | −0.59 (−2.6–1.4) | >0.1 | 0.01 (−0.1–0.1) | >0.1 | — | — |
| Hispanic | −1.75 (−3.6–0.1) | 0.06 | −0.06 (−0.1–0.0) | 0.03 | −0.18 (−0.4–0.1) | >0.1 |
| Asian | −2.78 (−7.3–1.8) | >0.1 | −0.02 (−0.1–0.1) | >0.1 | 0.01 (−0.2–0.2) | >0.1 |
| Insurance | ||||||
| Private | ref | — | ref | — | ref | — |
| Medicaid | −0.30 (−1.8–1.2) | >0.1 | −0.01 (−0.1–0.0) | >0.1 | 0.12 (−0.1–0.3) | >0.1 |
| Self-pay | 0.02 (−3.5–3.5) | >0.1 | 0.04 (−0.1–0.2) | >0.1 | — | — |
| Obesity-related illnesses, N | ||||||
| 0 | ref | — | ref | — | ref | — |
| 1–2 | 0.18 (−1.8–2.2) | >0.1 | −0.02 (−0.1–0.1) | >0.1 | −0.19 (−0.7–0.3) | >0.1 |
| 3–4 | −0.05 (−2.0–2.0) | >0.1 | −0.04 (−0.1–0.1) | >0.1 | −0.40 (−0.9–0.1) | 0.08 |
| 5–6 | 0.07 (−2.3–2.4) | >0.1 | −0.06 (−0.2–0.1) | >0.1 | — | — |
| ≥6 | 0.98 (−3.5–5.5) | >0.1 | −0.13 (−0.3–0.1) | >0.1 | −0.46 (−1.1–0.2) | >0.1 |
*
Coefficient indicates difference between respective medication and the overall frequency-weighted mean.
‡
N, patients with both pre-medication and post-medication weights recorded in chart. ref, reference group. Bold and italic value represents means-statistically significant.